NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS
PR Newswire
HOUSTON, Nov. 7, 2024
-- TOTAL REVENUE OF $222.3 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS.
$178.0 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 25%
-- HOSPITAL DIVISION VISITS OF 122,944 FOR THE FIRST NINE MONTHS OF 2024 VS.
VISITS OF 102,798 FOR THE SAME PERIOD IN 2023, AN INCREASE OF 20%
-- HOSPITAL DIVISION OPERATING INCOME OF $54.7 MILLION FOR THE FIRST NINE
MONTHS OF 2024 VS. $21.1 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE
OF 159%
-- NET CASH FROM OPERATING ACTIVITIES OF $23.1 MILLION FOR THE FIRST NINE
MONTHS OF 2024
-- COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOW
HOUSTON, Nov. 7, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in ten states and primary care-centric, risk-bearing physician networks, today announced third quarter 2024 financial results for the three and nine months ended September 30, 2024.
Financial Highlights for the Three Months Ended September 30, 2024:
-- Total revenue of $78.8 million as compared to total revenue of $62.7
million for the three months ended September 30, 2023, an increase of
26%. Of this revenue growth, mature hospitals, which are hospitals opened
prior to December 31, 2021, increased by 20.7% in 2024 compared to the
same period in 2023.
-- Operating income (including the negative impact of a $2.0 million
non-cash stock-based compensation expense) for the three months ended
September 30, 2024 was $9.7 million, compared to an operating loss of
approximately $0.8 million for the three months ended September 30, 2023,
representing a $10.5 million improvement quarter over quarter.
-- Net loss attributable to Nutex Health of $8.8 million in the three months
ended September 30, 2024 as compared to a net loss attributable to Nutex
Health of $5.5 million for the three months ended September 30, 2023.
This $8.8 million amount includes a $6.7 million non-cash loss on warrant
liability as well as the $2.0 million non-cash stock-based compensation
expense noted above.
-- EBITDA attributable to Nutex Health of $4.3 million, as compared to
EBITDA attributable to Nutex Health of $1.2 million for the three months
ended September 30, 2023.
-- Adjusted EBITDA attributable to Nutex Health of $13.5 million, as
compared to Adjusted EBITDA attributable to Nutex Health of $1.3 million
for the three months ended September 30, 2023, an increase of 938%.
-- Total visits from the Hospital Division were 41,668 for the third quarter
2024, as compared to 37,443 for the third quarter 2023, an increase of
4,225 or 11.3%. Of this visit growth, mature hospitals increased by 3.8%
in 2024 compared to the same period in 2023.
Financial Highlights for the Nine Months Ended September 30, 2024:
-- Total revenue of $222.3 million as compared to total revenue of $178.0
million for the nine months ended September 30, 2023, an increase of
approximately 25%. Of this revenue growth, mature hospitals, which are
hospitals opened prior to December 31, 2021, increased by 13.5% in 2024
compared to 2023.
-- Operating income for the nine months ended September 30, 2024 was $16.4
million compared to an operating loss of $5.6 million for the nine months
ended September 30, 2023, representing a $22.0 million improvement year
over year.
-- Net loss attributable to Nutex Health of $9.5 million as compared to net
loss attributable to Nutex Health of $14.2 million for the nine months
ended September 30, 2023. This $9.5 million amount includes non-cash
items of $10.2 million (non-cash stock-based compensation expense of $2.0
million, non-cash impairment of assets of $3.9 million, non-cash
impairment of goodwill of $3.2 million and $1.1 million non-cash loss on
warrant liability) in the first nine months of 2024, while the $14.2
million amount includes non-cash stock-based compensation expense of $2.2
million in the first nine months of 2023.
-- EBITDA attributable to Nutex Health of $19.9 million, as compared to
EBITDA attributable to Nutex Health of $5.3 million for the nine months
ended September 30, 2023.
-- Adjusted EBITDA attributable to Nutex Health of $30.1 million, as
compared to Adjusted EBITDA attributable to Nutex Health of $7.7 million
for the nine months ended September 30, 2023, an increase of 290%.
-- Total visits from the Hospital Division were 122,944 for the nine months
ended September 30, 2024, as compared to 102,798 for the same period in
2023, an increase of 20,146 or 19.6%. Of this visit growth, mature
hospitals increased by 7.7% in the nine months ended September 30, 2024
compared to the same period in 2023.
-- Net cash from operating activities of $23.1 million for the nine months
ended September 30, 2024.
-- As of September 30, 2024, the Company had total assets of $438.5 million,
including cash and cash equivalents of $46.9 million and long-term debt
of $26.8 million.
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
"We are pleased to report 25% revenue growth, Adjusted EBITDA attributable to Nutex Health of $13.5 million and a 209% increase in gross profit to $21.9 million in the third quarter ended September 30, 2024, showing our continued focus on top line growth, increasing cash flow as well as improving profitability," stated Jon Bates, Chief Financial Officer of Nutex Health.
"Nutex Health had another outstanding quarter. The strategic and operational decisions we have made over the last nine months are driving this strong performance, as demonstrated by another quarter of year-over-year growth in revenue, EBITDA and Adjusted EBITDA as well as incremental growth in cash flow. We are confident that our momentum will continue and plan on growing our hospital and population health divisions responsibly as we drive value for our shareholders," stated Warren Hosseinion, M.D., President of Nutex Health.
"The four de-novo hospitals that we opened in 2023 are ramping up nicely, resulting in strong year-over-year growth in both revenue and patient volume. Volumes and revenue continue to increase among our mature hospitals, both on the outpatient side as well as the inpatient side, which still have excess capacity. Our average payment by insurers of patient claims also increased, a trend we are optimistic will persist as we continue to work the NSA (No Surprises Act) claims through the Independent Dispute Resolution process," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
For more details on the Company's Third Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.
NUTEX HEALTH INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, 2024 December 31, 2023
-------------------- -------------------
Assets
Current assets:
Cash and cash equivalents $ 46,909,281 $ 22,002,056
Accounts receivable 62,745,336 58,624,301
Accounts receivable - related
parties 3,602,189 4,152,068
Inventories 2,259,168 3,390,584
Prepaid expenses and other
current assets 4,279,360 2,679,394
---------------- ---------------
Total current assets 119,795,334 90,848,403
Property and equipment, net 78,246,467 81,387,649
Operating right-of-use assets 11,442,369 11,853,082
Finance right-of-use assets 198,462,381 176,146,329
Intangible assets, net 15,855,392 20,512,636
Goodwill, net 13,918,719 17,066,263
Other assets 767,942 431,135
---------------- ---------------
Total assets $ 438,488,604 $ 398,245,497
================ ===============
Liabilities and Equity
Current liabilities:
Accounts payable $ 10,320,933 $ 18,899,196
Accounts payable - related
parties 6,342,883 6,382,197
Lines of credit 3,384,517 3,371,676
Current portion of long-term
debt 10,499,532 10,808,721
Operating lease liabilities,
current portion 2,060,758 1,579,987
Finance lease liabilities,
current portion 5,261,458 4,315,979
Accrued expenses and other
current liabilities 29,688,665 12,955,296
---------------- ---------------
Total current liabilities 67,558,746 58,313,052
Long-term debt, net 26,801,811 26,314,733
Warrant liability 5,715,143 -
Operating lease liabilities,
(MORE TO FOLLOW) Dow Jones Newswires
November 07, 2024 17:09 ET (22:09 GMT)
Comments